Background: Sickle cell disease (SCD) is consequently associated with increased rates of infant and childhood morbidity and mortality. Therefore, early detection is a crucial aspect of managing SCD to mitigate complications and improve health outcomes for SCD children. Neonatal screening is the primary method for identifying newborns with SCD, enabling early diagnosis, family screening, and comprehensive medical care. The protocol presented in this paper describes a study aimed at screening newborns for SCD in high-prevalence SCD states of India to understand the magnitude of the problem and the benefits of early comprehensive care along with the genotypic and phenotypic correlation. Methods: A prospective cohort study will be conducted across seven sites in six states of India (Rajasthan, Odisha, Tamil Nadu, Maharashtra, Madhya Pradesh, and Gujarat), having a high prevalence of SCD. The cord blood or heel prick samples of all the live-born babies delivered within the facilities of selected regions will be collected for screening SCD by HPLC (High-Performance Liquid Chromatography). All the sickle cell homozygous (SS) babies will be confirmed at 6 weeks for Sickle genotype along with cascade screening. Further, SS babies will be followed up from six weeks up to five years of life with initiation of folic acid, antibiotic prophylaxis, and hydroxyurea treatment at appropriate times. Results: The protocol aims to lay the groundwork for the smooth implementation of newborn screening programs and effective follow-up strategies. Conclusions: It will pave the way for developing a strategic framework for implementing newborn screening programs for haemoglobinopathies in India.
Sickle cell disease (SCD) is a major Public Health concern in India with highest prevalence amongst the tribal ethnic groups. It is an autosomal recessive disorder which results in haemoglobin polymerisation leading to sickle shaped red blood cells. It can manifest as SCD (Hemoglobin SS [HbSS]), Sickle Cell Trait (HbSS) or Sickle β-Thalassemia (HbS). HbSS is the most severe form, presenting as vaso-occlusion crisis, chronic hemolysis, eventually resulting in progressive multiorgan damage. Given the diversity of clinical presentation, SCD poses a considerable burden on health care system. National Sickle Cell Anemia Elimination Mission (NSCEM) launched by Government of India in 2023 proposes comprehensive framework for SCD screening, diagnosis and management. This article provides an overview of recent updates on SCD, existing programmatic challenges and future directions for advancing sickle cell care in India. Although geospatial epidemiology has been well understood, the reach at the grassroots level has been impacted by lapses in implementation leading to difficulty in health care access in remote tribal regions. The review highlights the need of identifying context-specific gaps and developing an evidence-based optimal model for SCD screening, diagnosis, treatment, and care. Further, newborn screening clubbed with timely follow up ensuring continuum of care can be programmatically measured as a composite care continuum index for every diseased child tracking from diagnosis till treatment initiation. While innovations in point of care testing for SCD diagnosis and liquid oral formulation of hydroxyurea for treatment are promising, there is imperative need of efforts towards improving overall quality of life of SCD individuals, spanning beyond medical management. Integrating Social and Behavioural Change Communication and Advocacy, Communication and Social Mobilization may culminate in the socio-cultural transformation for long-term success. With a robust political commitment, microplanning strategies, intersectoral collaboration, and community participation, NSCEM, India can serve as a global model for sickle cell control in low resource settings.